Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192428 | 1.00 | ABCG2 (0.69) | ABCG2MEN1POLBKMT2AMAPT | |
| SCHEMBL3173761 | 0.90 | TNFRSF1A (0.72) | ABCG2MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL3173746 | 0.90 | TNFRSF1A (0.72) | ABCG2MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL11959782 | 0.88 | ABCG2 (0.72) | ABCG2MEN1POLBKMT2AMAPT | |
| SCHEMBL3192374 | 0.85 | MAPT (0.70) | ABCG2MEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL3192360 | 0.85 | MAPT (0.70) | ABCG2MEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL13480862 | 0.85 | POLB (0.58) | ABCG2MEN1POLBKMT2AMAPT | |
| SCHEMBL13480875 | 0.83 | POLB (0.56) | ABCG2MEN1POLBKMT2AMAPT | |
| SCHEMBL28549138 | 0.83 | ABCG2 (0.71) | ABCG2MEN1POLBKMT2AMAPT | |
| SCHEMBL13776922 | 0.82 | MAPT (0.86) | ABCG2MEN1KMT2AMAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100028262-A1 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | SPEAR THERAPEUTICS LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100028262-A1 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | SPEAR THERAPEUTICS LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100028262-A1 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | SPEAR THERAPEUTICS LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-7598294-B2 | Antiproliferative agents; antiinflammatory agents; anticancer agents; diagnosis, therapy | SPEAR THERAPEUTICS LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598294-B2 | Antiproliferative agents; antiinflammatory agents; anticancer agents; diagnosis, therapy | SPEAR THERAPEUTICS LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598294-B2 | Antiproliferative agents; antiinflammatory agents; anticancer agents; diagnosis, therapy | SPEAR THERAPEUTICS LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20040254149-A1 | 3, 4-Methylenedioxy-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2004-12-16 | — | — | US | disclosed |
| EP-1432413-A2 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028713-A2 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254149-A1 | 3, 4-Methylenedioxy-substituted chalcones as therapeutic agents | OXER1, CCNO, CCNB3 | ABCG2 284/4885MEN1 3348/4885POLB 2381/4885 |
| US-20100028262-A1 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | RB1, BCL3, CCNO | ABCG2 723/4885MEN1 1696/4885POLB 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.